Back to Agenda
ACTIV: A Public-Private Partnership to Speed COVID-19 Therapies and Vaccines
Session Chair(s)
Robin M. Weinick, PhD
SVP/Managing Director Americas and Global Program Officer, DIA, United States
The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership brings together senior leaders from the Foundation for the National Institutes of Health (FNIH), NIH, FDA, BARDA, CDC, EMA, and the pharmaceutical industry to advance vaccines and therapies for COVID-19. The goal for the ACTIV partnership is to develop a framework to prioritize vaccine and therapeutic candidates in development and connect clinical trial networks to test new and repurposed candidates. In this session, representatives from the NIH, BARDA, EMA, FDA, and industry will provide an overview of the activities that are being undertaken by the ACTIV partnership.
Learning Objective : Describe how government and industry are collaborating to develop an international strategy for a coordinated research response to the COVID-19 pandemic; Discuss how a collaborative framework will prioritize vaccine and drug candidates, streamline clinical trials, coordinate regulatory processes, and/or leverage assets.
Speaker(s)
Peter Marks, MD, PhD
Senior Vice President, Molecule Discovery and Head of Infectious Disease, Eli Lilly and Company, United States
FDA Update
Thomas Hudson, MD
Senior Vice President, Research and Development, and Chief Scientific Officer, AbbVie, United States
Industry Update
David Wholley, MA
Senior Vice President of Research Partnerships, Foundation for National Institutes of Health (FNIH), United States
FNIH Update
Have an account?